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Crystal Structures of Two I-Ad±Peptide Complexes
Reveal That High Affinity Can Be Achieved
without Large Anchor Residues
I-A molecules (Campbell and Milner, 1993; Tisch and
McDevitt, 1996), it is of great interest to determine
whether any specific structural features of this important
family can be correlated with autoimmune disease.
For most class I and class II MHC molecules, specific
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and charge (Saper et al., 1991; Matsumura et al., 1992).
In general, the anchor residues in peptides bound by
class II MHC molecules, as for those bound by class I,Summary
are located within a nine-residue ªcoreº motif (Ram-
mensee et al., 1995). DR3, for example, has a hydropho-We have determined the structures of I-Ad covalently
bic residue (leucine, isoleucine, phenylalanine, methio-linked to an ovalbumin peptide (OVA323±339) and to an
nine, or valine) at the first position of the nine-residueinfluenza virus hemagglutinin peptide (HA126±138). The
motif, aspartic acid at the fourth position, and tyrosine,floor of the peptide-binding groove contains an un-
phenylalanine, or leucine in the ninth position. Surpris-usual b bulge, not seen in I-E and DR structures, that
ingly, peptides that bind to certain alleles of I-A, such asaffects numerous interactions between the a and b
I-Ad and I-Ab,do not appear to have as clearly identifiablechains and bound peptide. Unlike other MHC±peptide
nine-residue sequence binding motifs (Rammensee etcomplexes, the peptides donot insertany large anchor
al., 1995), implying that the requirement for their MHCresidues into the binding pockets of the shallow I-Ad
class II pocket interactions may not be as stringent asbinding groove. The previously identified six-residue
for other class II MHC molecules.ªcoreº binding motif of I-Ad occupies only the P4 to
OVA323±339 is responsible for 25%±35% of the T cellP9 pockets, implying that specificity of T cell receptor
response in BALB/c mice immunized with whole oval-recognition of I-Ad±peptide complexes can be accom-
bumin (Shimonkevitz et al., 1984) and has been exten-plished by peptides that only partially fill the MHC
sively used to study the nature of class II MHC±peptidegroove.
binding and T cell activation (Sette et al., 1987). HA126±138
is an immunodominant peptide of influenzavirus hemag-Introduction
glutinin that binds to I-Ad (Gerhard et al., 1991), and
the I-Ad±HA complex is recognized by the T2.5-5 T cellClass II major histocompatibility complex (MHC) mole-
receptor (TCR) transgenic mouse (Scott et al., 1994).cules are type I membrane glycoproteins that bind pep-
The OVA and HA peptides form stable complexes withtide fragments derived from exogenous protein sources,
I-Ad. Dissociation of I-Ad±OVA complexes is nearly mono-including viral and bacterial pathogens, and transport
phasic at 378C, with a half-life of 33 hr (Witt and McCon-them to the cell surface for recognition by helper T cells
nell, 1994). HA has similar affinity for I-Ad (Sette et al.,(reviewed by Cresswell, 1994). Unlike class I MHC mole-
1989b).cules, class II MHC molecules are found only on a limited
We have expressed soluble I-Ad in a recombinant formnumber of cell types. These specialized antigen-pres-
(Scott et al., 1996) and extended this work to produceenting cells express three genetically distinct isotypes
I-Ad with either the OVA323±339 (ISQAVHAAHAEINEAGR)of class II MHC molecules in humans (HLA-DR, HLA-
or the HA126±138 (HNTNGVTAASSHE) peptide attached byDQ, and HLA-DP), and two in mice (I-E and I-A). At
a six-residue linker (GSGSGS) to the first residue of thepresent, structural information on class II MHC mole-
I-Ad b chain (Scott et al., 1998), as first described forcules is restricted to the HLA-DR isotype (Brown et al.,
I-Ek and I-Ad by Kappler and coworkers (Kozono et al.,1993; Stern et al., 1994; Ghosh et al., 1995; Jardetzky
1994; reviewed by Wilson, 1994). In this report, we de-et al., 1996; Dessen et al., 1997; Murthy and Stern, 1997)
scribe the crystal structures of I-Ad±OVA and I-Ad±HAand its murine homologue, I-E (Fremont et al., 1996).
that have been determined at 2.6 and 2.4 AÊ resolution,Based on protein sequence comparisons, HLA-DQ and
respectively.its murine homologue I-A are anticipated to have overall
structures similar to I-E and DR molecules, but to differ
in a number of important structural details (Brown et al., Results
1988; Brown et al., 1993; Paliaksis et al., 1996). Since
strong genetic associations with autoimmunity have Summary of Distinctive Structural Features of I-Ad
been established between certain alleles of HLA-DQ and As seen in previously studied MHC molecules, the I-Ad
peptide-binding site is formed by two long antiparallel
a-helical segments that sit on top of and traverse an‖ To whom correspondence should be addressed (e-mail: wilson@
scripps.edu). eight-stranded antiparallel b sheet. The most unusual
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peptides in the MHC groove. First, neither peptide uses
large side-chain residues to anchor the peptide into
the peptide-binding groove. In both complexes, the key
interaction appears to be insertion of a valine side chain
into the central P4pocket of the MHC molecule, a finding
in full agreement with peptide-binding studies. Second,
with one exception, all hydrogen bonds (H bonds) be-
tween I-Ad and peptide are to the peptide backbone,
revealing an essentially sequence-independent H bond
network.
Overall Structure of the Complexes
The a and b polypeptide main chains of I-Ad are similar
in their overall fold to those previously reported for hu-
man and mouse class II MHC molecules. Thirteen resi-
dues of each covalently attached peptide had interpret-
able electron density. The amino-terminal domains of
each chain, a1 and b1, form a characteristic peptide-
binding groove that was initially described for human
(Bjorkman et al., 1987) and mouse (Fremont et al., 1992)
MHC class I molecules (Figure 1). The I-Ad b2 domain is
moderately rotated, compared to other class II struc-
tures, with a main-chain root-mean-square deviation
(rmsd) as large as 4 AÊ . The putative CD4 binding site,
residues b137±b143 (KoÈ nig et al., 1992), has a conforma-
tion that is similar to that of previous class II structures.
The top surface of the a helices of the I-Ad peptide-
binding groove, which would be accessible for interac-
tion with the TCR, appears electrostatically neutral,
similar to the DR1 helices and in contrast to the electro-
negative properties of the I-Ek helices.
Figure 1. Unusual Features of the I-Ad Peptide-Binding Groove
The OVA and HA peptides are bound to I-Ad in an
(A) A view is shown along the I-Ad peptide-binding groove (from C extended type II polyproline conformation (Figure 2), as
to N of the peptide) to highlight the interaction of theb bulge, located
previously observed in other class II structures (re-in the b-sheet floor of the peptide-binding groove, with the central
viewed by Wilson, 1996), with an rmsd of 0.75 AÊ for allportion of the peptide (yellow). The a subunit is represented in
magenta and the b subunit in cyan. Surprisingly, despite the bulge, corresponding peptide main-chain atoms. Two addi-
the peptide is pulled deeper into the groove via H bonds with the tional residues (Arg-Gly) from the signal sequence re-
main-chain atoms of the b-bulge residues, unimpeded in its down- main connected to the amino terminus of each peptide.
ward movement because a glycine residue is used at the center of
The covalent linker attaching the peptide to the b chainthe bulge. The OVA-specific H bond between residue a61Gln and
is disordered in both complexes. The OVA peptide se-the P5 histidine residue of the peptide is also shown.
quence extends to the P21 position, with additional(B) Tertiary structure differences between I-Ad (cyan) and HLA-DR1
(magenta). The structure is viewed into the peptide-binding groove density for a glycine from the signal sequence at the
to show the inward movement of the I-Ad a helices compared to P22 position and main-chain density for an arginine at
DR1. Proline a56 (red) may contribute to the helix movement in the the P23 position (which was modeled as an alanine
a chain of I-Ad. The location of the polymorphic b65±b67 region residue). The HA peptide sequence extends to the P22
(Pro65±Glu66±Ile67) is shown in yellow, close to another inward
position with density for the signal sequence glycinemovement of the b2 H2a helix. The p-helix segment (green) allows
visible at the P23 position. The first two residues of thethe insertion of b84Glu into the b1 H2b helix.
HA peptide are raised as a result of being a crystal
contact for a symmetry-related I-Ad±HA molecule. At thefeature of the I-Ad structure is a bulge in the floor of the
other end, electron density is visible for residues up topeptide-binding groove, due to the insertion of an I-A/
the P11 position and accounts for all of the HA126±138DQ±specific glycine in the first strand of the a chain.
residues but only 12 (OVA323±334) of the 17 OVA323±339 resi-The b bulge makes a number of interactions that draw
dues. Approximately 66% of the HA peptide surfacethe central portion of both peptides deeper into the
area is buried by I-Ad (744 AÊ 2 of 1118 AÊ 2; probe radiuspeptide-binding groove compared to DR± and I-E±pep-
1.7 AÊ ), and 70% of the OVA peptide (800 AÊ 2 of 1152 AÊ 2),tide structures. The presence of I-A±specific polymor-
comparable with other class II MHC±peptide com-phism in the two a-helical walls of the peptide-binding
plexes, which range from 62% (I-Ek-Hsp) to 70% (DR3-groove appears to narrow the groove. Residues shown
CLIP; Ghosh et al., 1995).to be involved in I-Ad mismatched chain pairing are lo-
cated primarily at the interface of the a and b subunits
on the floor of the peptide-binding groove in the vicinity The I-Ad Peptide-Binding Groove
The most distinctive feature of the I-Ad structure, com-of the distinctive b bulge.
Two striking features relate to the alignment of the pared to the other class II HLA-DR and I-E molecules,
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segments, which are not present in DR and I-E mole-
cules. The I-Ad a1 helical axis (a56±a77) is translated
inward, toward the center of thebinding site, by as much
as 1.2 AÊ relative to the DR1±HA complex. This movement
appears to be at least partially attributable to the con-
strained geometry of a proline at residue a56, unique
to I-A and DQ molecules, which is used as an a-helix
initiation site. The inward movement of the a helix is
stabilized by an I-A±specific H bond between the car-
bonyl O of the b-bulge a9Gly and the NHd2 of a62Asn
in the a1 helix (Figure 1A). Mutation of a56Pro of I-Ak to
alanine results in a loss of peptide-binding ability (Nel-
son et al., 1996). Other MHC-like structures, such as the
neonatal Fc receptor (Burmeister et al., 1994) and CD1
(Zeng et al., 1997), have proposed proline-related move-
ment of a-helical segments that are amino-terminal to
the proline.
A number of distinctive features in the segmented b1
helices of I-Ad also contribute to alteration of the pep-
tide-binding groove. Relative to DR1, the orientation of
the I-Ad H2a segment (b65±b77) is translated inward by
as much as 2.6 AÊ in the vicinity of another proline at
position b65. Residues b67Ile and b71Thr, which form
one side of the P7 pocket, have smaller side chains
compared to I-Ek residues, b67Phe and b71Lys, and
allow unimpeded inward movement of the I-Ad b1 H2a
a helix. Since DQ molecules lack b65Pro, it is anticipated
that they will have an H2a helix position more similar to
that seen in the DR structures, which also lack a proline
at b65.Figure 2. OVA and HA Peptide Electron Density and Conformation
Residue b65Pro is also the first residue in a serologi-(Top) The Fo2Fc shake-omit density maps are contoured at a 3 s
level for the OVA (gold) andHA (green) peptides, with the final refined cally immunodominant three-residue segment that is
peptides coordinates superimposed. (Bottom) A comparison of the polymorphic among I-A alleles (Buerstedde et al., 1989).
HA and OVA peptides bound to I-Ad, with peptides bound to other In I-Ad, and other alleles such as I-Ab, this segment is
class II MHC±peptide structures: the HA peptide (magenta) from the Pro65±Glu66±Ile67. The most common polymorphism
DR1±HA complex (Stern et al., 1994), and the Hb peptide (blue) from
has deletions at both b65 and b67, and a Tyr at b66, asthe I-Ek±Hb complex (Fremont et al., 1996). The I-Ad±bound peptides
seen in I-Ak and I-Ag7. In I-Ad, residues b65Pro and b66Glulie deeper in the groove than other class II bound peptides and have
project upward from the a helix and are likely sites forsmaller downward-pointing side chains that anchor these peptides
to the MHC molecule. TCR interaction, consistent with a report that residues
b65-b67 are necessary for recognition of I-Ad±OVA by
the T cell hybridoma DO-11.10 but do not control speci-
is the presence of a b bulge on the b-sheet floor of ficity of peptide binding to I-Ad (Lee et al., 1991). Residue
the peptide-binding domain (Figure 1A). The b bulge is b67Ile projects sideways into the groove and forms the
located in the first strand of the b sheet of a1, at the boundary of the shallow P7 pocket.
base of the P4 pocket. The b bulge is formed by two The most dramatic change in the b1 helix occurs at
residues that protrude above the b sheet: a8Tyr replaces the end of the H2b segment, b79±b84. The presence
a highly conserved a9Gln seen in the DR and I-E family of a proline at position b86 prevents a standard 3.613
of MHC structures, and a9Gly is an inserted residue not a-helical H bond to position b82, as seen in other class
seen in previous class II structures. An H bond is formed II structures. Instead, the carbonyl O at position b82
between the main-chain carbonyl oxygen (O) of a8Tyr now accepts an H bond from the backbone N at position
and the main-chain nitrogen (N) of the peptide P4 resi- b87, and similarly b83 H bonds to b88, thus forming a
due (Val327 in Figure 1A) and replaces two H bonds short 4.416, or p helix, that creates a kink between residues
made to the P4 residue of the peptide by the a9Gln seen b82 and b88. Within this p helix, a conformationally flexi-
in the DR1 and I-Ek structures. The outcome is a network ble glycine at b85 allows for insertion of a Glu at residue
of H bonds that pulls the central (P2±P8) region of the b84, compared to DR and I-E structures. Alignment of
I-Ad peptides deeper into the peptide-binding groove. class II b chain sequences predicted that this insertion
Sequence comparisons suggest that the b bulge will be would occur further along in the chain at the b strand
a conserved feature of I-A and HLA-DQ molecules. connecting the b1 and b2 domains (Klein, 1986). How-
The two long helical segments of I-Ad, which form the ever, the sequence register of the H3 helix can be
walls of the binding groove, are closer together and changed such that the insert occurs much earlier, at
present a narrower groove than is seen in other class II residue 84. Residue b84Glu is located on the outer side
structures (Figure 1B). The inward movement of both of the H2b segment. The b85Gly±b86Pro sequence is
helices appears to be due to the acquisition of particular found in a number of I-A alleles, including I-Ad and I-Ab,
but not I-Ak.proline residues and other side chains in the a-helical
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not form any H bonds, either directly or through water
molecules, to thebackbone of the HA and OVA peptides.
In contrast, a direct H bond between b57Asp and pep-
tide is seen in the HLA-DR1 and DR3 peptide complexes
(Stern et al., 1994; Ghosh et al., 1995; Murthy and Stern,
1997), while a water-mediated H bond between b57Asp
and peptide is seen in the I-Ek±Hb complex (Fremont et
al., 1996). In the I-Ad±HA complex, a water-mediated H
bond is seen between a76Arg and peptide, instead of
a direct a76Arg-to-peptide H bond seen in other HLA-
DR1, DR3, and I-Ek class II MHC±peptide complexes.
The altered H bond pattern between I-Ad and the car-
boxy-terminal region of the peptide appears to be
caused by a shallow P9 pocket and a new H bond be-
tween a68His and the P9 O of the peptide, which to-
gether force the peptide main chain to sit higher in the
peptide-binding groove. We cannot, however, exclude
the possibility that the lack of H bonds is affected by
tethering of thepeptide by a covalent linker. Collectively,
these observations indicate that the primary role of
b57Asp is to stabilize the I-Ad ab heterodimer while not
making any direct contribution to stabilization of the
bound peptide.
The nature of the sequestered environment in and
around the P4 pocket is completely changed by the
presence of the b bulge; no water molecules are buried
in the I-Ad±HA complex that could establish the pH-
dependent H bond network seen in the I-Ek complexes
(Fremont et al., 1996). The I-Ad±OVA complex was crys-
tallized at pH 5.5 and the I-Ad±HA complex at pH 7.4.
The structure of the P4 pocket is essentially the same
for both complexes. Thus, we are led to the conclusion
that the modulation of I-Ad peptide binding cannot be
rationalized by the formation of pH-dependent H bond
Figure 3. Interactions of the OVA and HA Peptides with I-Ad networks within the P4 pocket. This observation may
be relevant to previous results that showed that optimalAll residues that are in van der Waals contact with both OVA (A)
and HA (B) are numbered in pink. The Ca backbone of the I-Ad peptide binding by I-Ad occurs at a higher pH than for
peptide-binding domain is represented by the gray tube. I-Ad side- I-Ed, I-Ek, and I-Ak (Runnels et al., 1996).
chain interactions that are specific to each peptide are labeled in
red.
Peptide-Binding Motif of I-Ad
The I-Ad peptide-binding groove has only one moder-Fewer Interactions between I-Ad and Peptide
With few exceptions, I-Ad uses the same residues to ately large pocket, P1, between the main-chain atoms
of the peptide and the peptide-binding groove surfaceinteract with each peptide (Figure 3 and Table 1). I-Ad
forms fewer backbone H bonds to the bound peptide (Figure 5). Three smaller cavities, corresponding to the
P4, P6, and P9 pockets, can also be identified. Thecompared to DR1 (Stern et al., 1994), DR3 (Ghosh et al.,
1995), and I-Ek (Fremont et al., 1996) class II±peptide pocket structure of the I-Ad peptide-binding groove dif-
fers markedly from that of the I-Ek binding groove, wherecomplexes, and is comparable to the recent structure
of a DR4-CII complex (Dessen et al., 1997). With one the P4 and P9 pockets are the predominant sites occu-
pied by large peptide side-chain anchors (Figure 6). Un-exception, all H bonds between I-Ad and peptide are
to the peptide backbone. Fifteen H bonds are made like the DR1±HA structure, the largest pocket of I-Ad
accommodates peptide residues that only partially fillbetween I-Ad and OVA and 14 H bonds between I-Ad
and HA. Fourteen H bonds involve MHC residues that the P1 pocket.
Grey and coworkers have carried out extensive stud-are highly conserved in I-A sequences (Figure 4); 10 of
these H bonds involve I-Ad residues that are conserved ies to identify the binding motif of I-Ad (Sette et al., 1987,
1988, 1989a, 1989b, 1989c, 1990; Hunt et al., 1992).in most human and mouse class II proteins (Stern and
Wiley, 1994). The other four H bondsÐP4 N to the main- The core motif was proposed to be only six residues in
length, with the first, third, and fourth residues beingchain O of a8, P5 N to Oe b74Glu, P7 N to OHh of b30Tyr,
and P9 O to Ne2 of a68HisÐinvolve residues that are hydrophobic and the sixth residue generally being an
alanine or serine. In the I-Ad crystal structure, the six-conserved in all I-A and most DQ molecules.
In both I-Ad±peptide structures, b57Asp forms an in- residue core motif is positioned such that it extends
from the P4 pocket to the P9 pocket (Figure 5 and Tableterchain salt bridge to a76Arg, which is essential for
proper peptide binding and efficient surface expression 2). In the I-Ad±OVA complex, the large P1 pocket is occu-
pied only partially by Ser324, and the third-largest(Nalefski et al., 1995). Surprisingly, b57Asp of I-Ad does
Crystal Structures of I-Ad with OVA and HA Peptides
323
Table 1. H Bonds and van der Waals Interactions between I-Ad and the HA and OVA Peptides
Hydrogen Bonds van der Waals
P22 HA (His) a55Glu (Oe2←NHd1a) a53Leu a55Glu
OVA (Glyb) a53Leu (NH→O) a52Ala a53Leu
P21 HA (Asnc) b81His (NHe2→O) a53Leu b81His
OVA (Ile) b81His (NHe2→O) a53Leu b81His
P1 HA (Thr) a53Leu (O←NH) a54Phe b82Asn b86Pro
OVA (Ser) a53Leu (O←NH) a54Phe b82Asn b86Pro
P2 HA (Asn) b82Asn (Od1→NH), (NHd2→O) b77Thr b81His b82Asn
OVA (Gln) b82Asn (Od1←NH), (NHd2→O) a24His b77Thr b78Ala b81His b82Asn
P3 HA (Gly) a8Tyr a22Tyr a24His a54Phe
OVA (Ala) a8Tyr a22Tyr a24His a54Phe b78Ala
P4 HA (Val) a8Tyr(OHh←NH), a62Asn(NHd2→O) a8Tyr a9Gly b11Phe b74Glu b78Ala
OVA (Val) a8Tyr(OHh←NH), a62Asn(NHd2→O) a8Tyr a9Gly b11Phe b28Thr b74Glu
P5 HA (Thr) b74Glu(Oe←NH) a62Asn b11Phe b70Arg b74Glu
OVA (His) b74Glu(Oe←NH), a61Gln (Oe1←NHe2) a61Gln a62Asn b11Phe b70Arg b74Glu
P6 HA (Ala) a62Asn(Od1←N) a62Asn a65Ala b11Phe b30Tyr
OVA (Ala) a62Asn(Od1←N) a62Asn a65Ala b11Phe
P7 HA (Ala) a69Asn (NHd2→O), b30Tyr (OHh←NH) b30Tyr b61Trp
OVA (Ala) a69Asn (NHd2→O), b30Tyr (OHh←NH) a69Asn b30Tyr b61Trp
P8 HA (Ser) b61Trp(NHe1→O) a69Asn b61Trp
OVA (His) b61Trp(NHe1→O) a65Ala a68His a69Asn b60Tyr b61Trp
P9 HA (Ser) a69Asn(Od1←NH), a68His(NHe2→O) a68His a69Asn a72Ile b57Asp b61Trp
OVA (Ala) a69Asn(Od1←NH), a68His(NHe2→O) a68His a69Asn a72Ile b60Tyr
P10 HA (His) a72Ile b60Tyr
OVA (Glu) a72Ile b60Tyr
P11 HA (Glu)
OVA (Ile) a68His a72Ile
Residues in bold indicate interactions seen in I-Ad that are not present in previous class II±peptide structures. Underlined residues indicate
that other MHC class II molecules use this residue position but with a different side chain making contact with peptide.
a Hydrogen bonds are indicated from I-Ad atom to peptide atom. The direction of the arrow indicates donor→acceptor.
b Residue is from signal peptide sequence.
c Built as an alanine because no side-chain density is visible.
pocket, the P9 pocket, is filled only partially by Ala332. sitting between the P4 and P9 pockets. The HA peptide
partially fills the P1 (Thr128) and P9 (Ser135) pockets,Val327 sits firmly in the P4 pocket anchoring the peptide
register (Figure 6). The last four residues of the 17-mer with Val131 providing the only obvious side chain anchor
into the P4 pocket (Figure 5). Ser135 appears to com-OVA peptide, OVA336±339, are not visible in the electron
density map and presumably do not make any well- pensate for not filling the P9 pocket by forming a long
H bond (3.5 AÊ ) between its OHg and Od1 of aAsn69.defined contacts with I-Ad, consistent with a report that
OVA323±335 binds to I-Ad with an affinity equal to that of aAsn69 is a key residue that interacts with the peptide
backbone at P7 and P9 (Figure 4). Small P9 residuesOVA323±339 (Sette et al., 1987).The I-Ad±HA complex exhib-
its a similar pattern of binding, with its core motif also have been observed in the DR4-CII complex (glycine;
Dessen et al., 1997) and I-Ak±HEL (serine; Fremont et al.,
1998 [this issue of Immunity]). The six-residue covalent
linker is long enough to allow the 13-mer HA peptide to
occupy the entire MHC peptide-binding groove. The
OVA peptide has four additional residues compared to
the HA peptide and therefore should be able to interact
in all possible registers with the I-Ad groove. Conse-
quently, the register that we observe in the I-Ad±OVA
complex should represent the most energetically fa-
vored register adopted by the OVA323±339 peptide.
Residue Differences That Affect
Mismatched Allele Dimerization
The I-Ad b chain is particularly promiscuous in its abilityFigure 4. The Conserved H Bonds between I-Ad and the Peptide
to dimerize with a chains and has been shown to formBackbone
mixed dimers with I-Ab, I-Ak, I-E, DR, DQ, and DP aThe H bonds occurring between the main-chain O of the b bulge
chains, whereas I-Ab and I-Ak b chains will form mixedand the P4 N of the peptide are partially obscured by peptide. For
clarity, only the a helices andfragments of the b structure are shown. dimers only with other I-A a chains (Lechler et al., 1990).
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Figure 5. The Peptide-Binding Pockets of I-Ad
A side view and a cross-section of the I-Ad±OVA (top) and I-Ad±HA
(bottom) complexes, showing the location of partially filled MHC
pockets. The peptide amino terminus is at the left. The central valine
at the P4 pocket in both complexes appears to fix the register for
the peptide. The P1 and P9 pockets are not filled by the OVA and
HA sequences.
As previously suggested (Lechler et al, 1990; Sant et al.,
1991 and references therein), the I-Ad structure reveals
that certain residues present in the first strand of the b1
domain play a direct role in dimerization (Figure 7). First,
b12Lys projects down from the b sheet and makes an
interchain H bond with the main-chain carbonyl O of
Figure 6. Comparison of Class II MHC Molecule Binding Pocketa140 in the a2 domain. I-Ak and I-Ab have glutamine and
Structuremethionine at b12, respectively, and are predicted not
The location, size, and occupancy of the pockets in the peptide-to make this H bond. Second, residue I-Ad b9Val inter-
binding groove of I-Ad in comparisonwith other class II MHC±peptide
acts with the a1 helix at polymorphic residue a66Glu. In structures: I-Ad±OVA complex (gold), I-Ek±Hsp complex (blue),
I-Ab and I-Ak b9 is a tyrosine and histidine, respectively. DR1±HA complex (magenta), and DR3-CLIP (cyan). Both I-E and
Consequently, the b chains of I-Ab and I-Ak will pack I-A molecules use a prominent P4 pocket, in contrast to the DR
molecules. In contrast to the other MHC molecules, I-Ad does notcorrectly only with a chains having a small side chain
use its largest pocket, located at P1, to anchor the OVA peptide into(valine or glycine) at residue a66, whereas the I-Ad b
the peptide-binding groove. The coordinates used were I-Ek±Hspchain is able to interact with all a chains without a steric
(Fremont et al., 1996; PDB accession code 1IEB), DR1±HA (Stern
clash with residue a66. Third, the conformationally flexi- et al., 1994; PDB accession code 1DLH), and DR3-CLIP (Ghosh et
ble b13Gly sits adjacent to the b bulge in the first strand al., 1995; provided by Partho Ghosh and Don Wiley).
of a1 at the base of the P4 pocket. Residue b13 is an
inflexible proline in I-Ak that most likely alters the b-sheet
structure in and around the b bulge. Fourth, b14Glu fully buried in the P4 pocket and is making the key
hydrophobic interaction that sets the register of the pep-forms two H bonds with b16Tyr and b29Arg that appear
to stabilize the b-sheet structure of the b1 domain. tide within the groove. No clear residue motif has been
determined for the P1residue of I-Ad, implying that occu-
pancy of this pocket by residues of specific size andDiscussion
charge is not necessary for high-affinity peptide binding.
This agrees with our observations that neither the OVAThe peptide interactions in the I-Ad±OVA structure are
in full agreement with theexperimentally derived binding (Ser324) nor the HA (Thr128) peptide side chain fills the
P1 pocket. Ala326 (P3), Ala329 (P6), and Ala330 (P7) aredata of Grey and coworkers (Sette et al., 1987). The two
residues that were shown by mutagenesis to be most oriented sideways or slightly upward and establish a
hydrophobicsurface in the center of thepeptide-bindingimportant for I-Ad binding, Val327 and Ala332, are ori-
ented downward into the P4 and P9 pockets. These groove. Replacement of these residues with larger side
chains does not affect peptide binding to I-Ad but doespockets can accommodate small, uncharged peptide
side chains, and mutation of these residues to larger or hinder T cell recognition, consistent with the fact that
any further extension at the b carbon would have tocharged groups greatly reduces peptide binding (Sette
et al., 1987). Val327 of the I-Ad±OVA complex is almost project upward from the peptide-binding groove. The
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Table 2. Register of Full-Length and Truncated OVA and HA Peptides within the Pocket Structure of the I-Ad Peptide-Binding Groove
Peptide Register
P P P P P P P P P P P P P P
23 22 21 1 2 3 4 5 6 7 8 9 10 11
Core motifa h h h *
HA126±138b G H N T N G V T A A S S H E
HA128±138 (2.0)c T N G V T A A S S H E
HA126±136 (0.5)c H N T N G V T A A S S
OVA323±339b R G I S Q A V H A A H A E I N E A G R
OVA327±339 (0.3)d V H A A H A E I N E A G R
OVA323±332 (0.2)d I S Q A V H A A H A
Myo108±118 (8.0)e S E A I I H V L H S R
Nase101±114f E A L V R Q G L A K V A Y
l rcpt12±26 (1.0)g L E D A R R L K A I Y E K K K
Apo-E270±283 (0.4)h W A N L M E K I Q A S V A T N P I
YT core (10.0)i Y T Y T V H A A H A Y T Y T
YTA core (7.1)i Y T A V H A A H A A Y T
AM core (6.3)i A M A M V H A A H A A M A M
AK core (4.6)i A K A K V H A A H A A K A K
ROI (27.7)j V H A A H A V H A A H A V H A
ROIV (34.0)j A H A A H A A H A A H A A H A A
OVA alt 1 I S Q A V H A A H A E I N E A G R
OVA alt 2 I S Q A V H A A H A E I N E A G R
The register of HA126±138 and OVA323±339 (bold) was used to align other high-affinity peptides in the I-Ad peptide-binding groove. Immediately
below the HA and OVA peptides are the proposed alignment of truncated HA and OVA peptides. The last two lines show two alternative (alt)
alignments of OVA323±339. The remaining lines show the possible alignment of other high-affinity peptides. Where known, the relative binding
capacity of each peptide, compared to OVA323±339 binding, is given in parentheses.
a h, hydrophobic; asterisk, A/S.
b Underlined residues are from signal sequence.
c Sette et al., 1988, 1989b.
d Sette et al., 1987.
e Sperm whale myoglobin (Sette et al., 1988; England et al., 1995).
f Staphylococcal nuclease (Sette et al., 1987, 1989a).
g l phage receptor (Sette et al., 1989b).
h Mouse apolipoprotein (Hunt et al., 1992).
i Core extended-peptides (Sette et al., 1989c).
j High-affinity peptides (Sette et al., 1990).
two histidine residues, His328 (P5) and His331 (P8), methionine in the P1 pocket (Table 2). The P1 pocket
of I-Ad is large enough to accommodate the flexiblealong with the P21 residue, project out from the MHC±
peptide surface and are in excellent position to be T methionine side chain. Mouse CLIP85±101 has been ex-
tracted from purified I-Ad molecules (Hunt et al., 1992)cell epitopes. Mutagenesis studies identified the His
residues as critical for recognition by the T cell hybrido- and requires its methionine residues to bind I-Ad (Sette
et al., 1995). In the DR3-CLIP x-ray structure (Ghosh etmas 3DO-54.8 and 8DO-51.15 (Sette et al., 1987). The
I-Ad±HA complex provides further independent verifica- al., 1995), methionines occupy the P1 and P9 pockets.
Although the P1 pocket of I-Ad appears to be largetion that the register of the OVA peptide can be adopted
by other peptides and is most likely a general feature enough to accommodate a methionine, the P9 pocket
of I-Ad is smaller than in DR3 (Figure 6), forcing Met98of peptide binding by I-Ad.
The I-Ad±peptide structures can be used to predict of mouse CLIP to sit suboptimally in the P9 pocket. In
agreement with this proposition, mutation of Met99 tothe alignment of peptides known to bind I-Ad with high
affinity (Sette et al., 1988, 1989a; Hunt et al., 1992). A alanine enhances the affinity of CLIP for I-Ad (Gautam
et al., 1995).sperm whale myoglobin peptide (MYO102±118), for exam-
ple, would be predicted to place Ser117 in the medium- For DR molecules, most of thepeptide-binding energy
is due to H bonds to the peptide backbone and thesized P9 pocket, allowing the hydrophobic residue
Ile112 to sit in the P4 pocket (Table 2). The predicted interaction of at least one large hydrophobic side chain
anchor residue with an MHC pocket (Jardetzky et al.,agretopes and epitopes of the MYO peptide agree with
the conclusions derived from a mutational study of this 1990; Hill et al., 1994). I-Ad also binds peptides using a
number of H bonds to the peptide backbone, but unlikecomplex and a structure-based alignment (England et
al., 1995). As a second example, alignment of apolipo- other class II MHC±peptide structures,OVA and HA bind
I-Ad without the use of large side-chain anchor residues,protein-E268±283 peptide (Hunt et al., 1992) and a high-
affinity peptide that has an Ala±Met sequence repeated reducing the amount of buried peptide surface area.
Paradoxically, full occupancy of the P4 pocket appearson each side of the core OVA motif (AM core) places a
Immunity
326
leaving empty the P10 and P11 positions at the carboxy-
terminal end of the binding groove (Table 2). HA126±136
binds to I-Ad almost as well as OVA323±339 (Sette et al.,
1988). Similar logic can be applied to high-affinity, trun-
cated sperm whale myoglobin peptides (Sette et al.,
1988), high-affinity truncated l phage repressor pep-
tides (Sette et al., 1989b), and perhaps even the shorter
OVA324±334 peptide (Sette et al., 1989b). The implication
is that I-Ad is able to bind peptides with high affinity
without having the entire peptide-binding groove occu-
pied. Truncation studies of the OVA323±339 peptide reveal
a further level of complexity. Truncated OVA327±339 binds
with approximately one third of the affinity of OVA323±339.
Consequently, either I-Ad binds the amino-terminal
Figure 7. Structurally Important Residues in I-Ad ab Chain Dimer- Val327 in the P4 pocket, leaving a large proportion of
ization
the binding groove empty, or OVA327±339 binds I-Ad inA side view of I-Ad, showing some of the principal residues that play
alternative registers by placing suboptimal residues ina role in determining the degree of mixed ab chain pairing. Most of
the P4 and P9 pockets (Table 2).the residues identified are polymorphic within the I-A isotype. The
A number of murine autoimmune diseases require ex-a subunit is shown in magenta, and the b subunit is shown in blue.
The b bulge is highlighted in green. The H2a helix of the b subunit pression of specific I-A alleles for disease onset. The
has been omitted to reveal the close association of a66Glu with best case is I-Ag7, associated with insulin-dependent
b8Val. diabetes mellitus (reviewed by Tisch and McDevitt,
1996) and more recently with murine rheumatoid arthritis
(Kouskoff et al., 1996). Based on protein sequence com-
not to be an absolute requirement for peptide binding, parison, I-Ag7 should share strong structural similarity to
since mutation of the OVA residue Val327 to alanine I-Ad, since the a chain of I-Ad and I-Ag7 are the same,
does not significantly reduce binding affinity for I-Ad and only 17 residues differ between the I-Ad and I-Ag7 b
(Sette et al., 1989a). These observations contrast with chains, all located in the b1 domain. The absence of a
data from studies of the DR1±HA complex, in which proline at b56 in I-Ag7 would be predicted to destabilize
mutation of the key anchor residue, Tyr308, to alanine the orientation of the H1 segment of the b1 a helix.
severely reduced binding to DR1 (Jardetzky et al., 1990). Replacement of the I-Ad b57Asp with the I-Ag7 b57Ser
A number of natural (Hunt et al., 1992) and synthetic would destroy the salt bridge between b57Asp and
peptides (Sette et al., 1989c, 1990) have higher affinities a76Arg and probably destabilize the ab dimer. Since
for I-Ad than OVA323±339. Alignment of most of these pep- these salt bridge residues also form direct or indirect H
tides sequences with theHA and OVA peptides indicates bonds to the peptide backbone, I-Ag7 would be predicted
that increased binding occurs because the P1 pocket to present peptides whose carboxy-terminal portion
is now occupied by a larger peptide side chain (Table was loosely bound in the MHC groove. It is interesting
2). However, certain synthetic peptides (ROI and ROIV) that in HLA-DR4, an isotype specifically associated with
have a higher capacity to bind I-Ad than OVA323±339. These rheumatoid arthritis, no backbone interactions are made
peptides cannot fill the P1 pocket with a large side chain with b57Asp or a76Arg (Dessen et al., 1997). The pres-
without the unfavorable introduction of a histidine resi- ence of a histidine at residue b9 in I-Ag7, instead of a
due into the P4 pocket (Table 2). Surprisingly, alternative valine in I-Ad, would require the b9 side chain to occupy
alignments of these peptides will place alanines at the the P4 pocket in order not to collide with a66Glu, a
P1 and P9 pockets, filling the P4 pocket either with a residue implicated in ab dimerization. Consequently, the
valine or an alanine. It is possible, given the minimal P4 pocket used by I-Ad to align the HA and OVA peptides
side-chain requirements for peptide binding by I-Ad, that may be further reduced in size in I-Ag7, perhaps exclud-
these alanine-rich synthetic peptides can be bound in ing its use as a site for anchoring peptide side chains.
a number of alternative registers, forming a mixed popu- Finally, the replacement of the I-Ad tryptophan with the
lation of MHC±peptide complexes. Thus, while DR1 I-Ag7 tyrosine at residue b61 will remove the ability to
binds peptides that use a single large side-chain interac- form an H bond to the peptide main chain O of the P8
tion to increase affinity, I-Ad selectively binds peptides residue that is important in class I and class II molecules
with small, hydrophobic side chains that avoid steric (reviewed by Stern and Wiley, 1994). Thus, a number of
clashes in the center of the binding groove. residues that differ between I-Ad and I-Ag7 are located
Results from the I-Ad±peptide structures and a number at sites that are important for establishing proper ab
of I-Ad±peptide-binding studies suggest that I-Ad readily chain dimerization and peptide binding in the I-Ad±
binds peptides that only partially fill the peptide-binding peptide complexes.
groove. Alignment of the truncated peptide HA128±138 with
the six-residue I-Ad motif would place Thr128 in the P1
Experimental Procedurespocket, leaving empty the region of the peptide-binding
groove that binds the P21 and P22 peptide residues
DNA Constructs, Protein Purification, and Crystallization
(Table 2). Surprisingly, HA128±138 binds to I-Ad with similar A leucine zipper±hexahistidine tail was added to the coding region
affinity as OVA323±339 (Sette et al., 1988). Conversely, for the extracellular domains of the I-Ad a and b chains as previously
described (Scott et al., 1996). The I-Ad b chain DNA sequence wasSer136 of the 11-mer HA126±136 would sit in the P9 pocket,
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Table 3. X-Ray Crystallographic Data and Statistics for the I-Ad±OVA and I-Ad±HA Structures
I-Ad±OVA323±339 I-Ad±HA126±138
Crystallization conditions 32% PEG 600 19% PEG 8000
0.1 M imidizole malate (pH 5.5) 0.2 M Tris (pH 7.4)
Space group P41212 C2
Cell constants a 5 b 5 101.3 AÊ , a 5 127.2 AÊ , b 5 100.2 AÊ ,
c 5 92.6 AÊ c 5 53.1 AÊ , b 5 100.38
Rsym (I) 5.7% 7.6%
Last shell 38.3% (2.7±2.6 AÊ ) 25.9% (2.5±2.4 AÊ )
Fo $ 0 s no. (% completness) 14,777 (99%) 22,555 (89%)
Last shell 1,690 (91%) 2,820 (88%)
Fo $ 2 s no. (% completness) 14,001 (91%) 21,229 (83%)
Last shell 1,400 (75%) 2,390 (74%)
Protein 1 peptide atoms a1±178, b6±188a a1A-178,b b5-188a
3,026 3,100
Water molecules 9 114
Carbohydrates 1 (Asnb19) 0
Refinement resolution 27.0 to 2.60 AÊ 24.0 to 2.40 AÊ
Rfree for F$ 0s (F $ 2s) 32.0% (31.1%) 30.8% (29.4%)
Last shell 45.6% (38.8%) 37.5% (33.3%)
Rcryst for F $ 0s (F $ 2s) 25.5% (24.6%) 25.3% (24.1%)
Last shell 41.2% (35.3%) 35.6% (31.0%)
,B. 51 AÊ 2 30 AÊ 2
rmsd bond length 0.012 AÊ 0.009 AÊ
rmsd bond angle 2.68 1.88
rmsd dihedral 29.28 29.78
a First two residues of an eight-residue tail (SSADLVPR), which remained after removal of an engineered leucine zipper by thrombin digestion
(Scott et al., 1996), are also modeled.
b All eight residues of the thrombin-digested leucine zipper tail are also modeled.
further modified to encode either the OVA or HA peptide sequence compared to the next-best solution, which had a correlation coeffi-
cient of 22.1% and an Rcryst of 0.56. DENZO was also used to deter-attached by a six-residue linker (GSGSGS) to the first codon of the
mature b chain. Both inserts were cloned into an expression vector mine that the space group of I-Ad±HA was C2 and was verified by
pseudoprecession analysis using XPREP (SHELXTL 5.03, Siemenswith a metallothionein-driven promoter (Scott et al., 1998).
The I-Ad a chain and I-Ad b chain constructs and a neomycin- Industrial Automation, Madison, WI, 1990±1995).
A molecular replacement solution was found for the I-Ad±HA com-resistance gene constructwere transfected into Drosophila melano-
gaster S2 cells. Soluble I-Ad was isolated from the growth media plex using AMoRe and the partially refined I-Ad±OVA complex as a
molecular probe.using Ni-NTA technology (Qiagen, Santa Clara, California). The pro-
tocols for protein expression, isolation, and purification have been Each complex was built independently. In the last round of build-
ing, the I-Ad±OVA and I-Ad±HA structures were superimposed anddescribed previously (Scott et al., 1998). Crystals were grown in
sitting drops by the vapor diffusion method (Stura and Wilson, 1992) compared. Model building was done in O (Jones et al., 1991) using
a combination of shake-omit 2Fo2Fc and Fo2Fc density maps. Re-at a fixed temperature of 228C using protein concentrations ranging
from 5 to 9 mg/ml. For low-temperature data collection, crystals finement was carried out with XPLOR version 3.8 (BruÈ nger, 1992).
Before model building was begun, both complexes were first refinedwere transferred into the same mother liquor, with 30% glycerol
added as cryoprotectant prior to cryocooling. using whole-molecule and then domain rigid body refinement. For
the I-Ad±OVA complex, five rounds of model building were carried
out in conjunction with the slow-cool refinement protocol of XPLORData Collection and Space Group Determination
As previously reported, a molecular replacement solution was found using all reflections between 8 and 2.6 AÊ . All reflections to 2.6 AÊ
were used to calculate electron density maps. Electron density wasfor the I-Ad±OVA complex using data collected from one crystal at
room temperature (Scott et al., 1998) and HLA-DR1 (Stern et al., seen for a single N-acetylglucosamine moiety at one of the three
putative N-linked carbohydrate sites, and one sugar was built into1994; Protein Data Bank, Brookhaven National Laboratory [PDB]
accession code1DLH) as a molecular probe. Higher resolution oscil- this density. Subsequently, bulk solvent correction was applied to
all reflections using XPLOR. Five rounds of model building combinedlation data for both complexes were collected at the Stanford Syn-
chrotron Radiation Laboratories using the in-house open-flow low- with positional and B-valuerefinement were carried out. Watermole-
cules were then identified from residual density greater than 2.2 stemperature cryostat to flash-cool the crystal to approximately 958K.
Data were collected on a MAR area detector and were indexed and in 2Fo2Fc maps using XPLOR. Each water molecule was checked
for validgeometry, environment, and correct shape of density beforescaled using DENZO (Otwinowski, 1993). Consistent with the space
group determination for the room temperature data, the highest proceeding to more rounds of model building, positional, and B-value
refinement (Table 3).symmetry space group found with DENZO for the I-Ad±OVA data
was primitive tetragonal. Using AMoRe (Navaza, 1994), the partially Three rounds of model building and slow-cool refinement were
done for the I-Ad±HA complex using all reflections between 8.0 andrefined I-Ad±OVA model was used as a search model for a molecular
replacement solutionwith the cryocooled data set indexed in P41212. 3.0 AÊ , followed by four rounds of model building and slow-cool
refinement with data between 8.0 and 2.4 AÊ . No convincing densityThe best rotation translation solution had a correlation coefficient
of 66.7% and an Rcryst of 0.37 (Rcryst 5 Shkl|Fo2Fc|/ShklFo, where Fo was visible for any of the putative N-linked sugar sites. Bulk solvent
correction was applied to all reflections, andseveral rounds of modeland Fc are observed and calculated structure factors, respectively)
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building and positional and B-factor refinement were done before Bjorkman, P.J. (1994). Crystal structure at 2.2 AÊ resolution of the
MHC-related neonatal Fc receptor. Nature 372, 336±343.water molecules were selected for inclusion in the model (Table 3).
Campbell, R.D., and Milner, C.M. (1993). MHC genes in autoimmu-
nity. Curr. Opin. Immunol. 5, 887±893.Analysis and Visualization
The quality of the final structure was assessed with the program Colovos, C., and Yeates, T.O. (1993). Verification of protein struc-
PROCHECK (Laskowski et al., 1993). The final I-Ad±OVA and I-Ad±HA tures: patterns of nonbonded atomic interactions. Protein Sci. 2,
models exhibit good stereochemistry, with 87.5% and 90.3% of the 1511±1519.
residues, respectively, in the most favored areas of the Ramachan- Cresswell, P. (1994). Assembly, transport, and function of MHC class
dran plot. The one outlier in both structures, b33Asn, corresponds II molecules. Annu. Rev. Immunol. 12, 259±293.
to a type II9 b turn, as seen in other class II MHC structures. The
Dessen, A., Lawrence, C.M., Cupo, S., Zaller, D.M., and Wiley, D.C.likelihood of correct I-Ad±peptide conformation was also checked
(1997). X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401)using ERRAT (Colovos and Yeates, 1993), which determines the
complexes with a peptide from human collagen II. Immunity 7,probability of pairwise interactions using a nine-residue sliding win-
473±481.dow. Atomic coordinates of class II molecules for structural compar-
England, R.D., Kullberg, M.C., Cornette, J.L., and Berzofsky, J.A.isons were obtained from the PDB, from Daved Fremont (Columbia
(1995). Molecular analysis of a heteroclitic T cell response to theUniversity, New York, NY) (I-Ek) or Don Wiley (Harvard University,
immunodominant epitope of sperm whale myoglobin: implicationsCambridge, MA) (DR3-CLIP). Structural superposition was per-
for peptide partial agonists. J. Immunol. 155, 4295±4306.formed using the program MIDAS (Ferrin, 1988) and OVRLAP (Ross-
mann and Argos, 1975). Superposition of the MHC class II structures Ferrin, T.E. (1988). The MIDAS display system. J. Mol. Graphics 6,
was done using residues in the b-sheet floor of the peptide-binding 13±27.
groove. The specific residues were a18±26, a29±34, b24±32, and Fremont, D.H., Matsumura, M., Stura, E.A., Peterson, P.A., and Wil-
b37±42, corresponding to the b strands that are conserved in all son, I.A. (1992). Crystal structures of two viral peptides in complex
class II MHC structures. Cavities formed between MHC and peptide with murine MHC class I H-2Kb. Science 257, 919±927.
were identified using MSMS (Sanner et al., 1996) with a probe radius Fremont, D.H., Hendrickson, W.A., Marrack, P., and Kappler, J.
of 1.4 AÊ . For cavity analysis, the peptide in each MHC class II± (1996). Structures of an MHC class II molecule with covalently bound
peptide complex was changed to a polyglycine chain, and the probe
single peptides. Science 272, 1001±1004.
was used to identify all cavities between MHC and polyglycine pep-
Fremont, D.H., Monnaie, D., Nelson, C.A., Hendrickson, W.A., andtide that could be used as pockets for peptide side chains. The
Unanue, E.R. (1998). Crystal structure of I-Ak in complex with alocation of the pockets with respect to the peptide was visualized
dominant epitope of lysozyme. Immunity 8, this issue, 305±317.using AVS (Advanced Visual Systems, Wiltham, MA). GRASP (Nich-
Gautam, A.M., Pearson, C., Quinn, V., McDevitt, H.O., and Milburn,ols et al., 1991) was used to analyze buried surfaces and to view
P.J. (1995). Binding of an invariant-chain peptide, CLIP, to I-A majorsurface electrostatics. All images wereproduced using AVS. Coordi-
histocompatibility complex class II molecules. Proc. Natl. Acad. Sci.nates have been deposited in the PDB with accession codes 1IAD
USA 92, 335±339.(I-Ad±OVA) and 2IAD (I-Ad±HA) and will be available until their release
by the PDB from wilson@scripps.edu. Gerhard, W., Haberman, A.M., Scherle, P.A., Taylor, A.H., Palladino,
G., and Caton, A.J. (1991). Identification of eight determinants in
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